Piper Sandler analyst Biren Amin raised the firm’s price target on Solid Biosciences (SLDB) to $18 from $17 and keeps an Overweight rating on the shares. In Q1 financial results, Solid reported that the first patient has been dosed in the Phase 3 IMPACT DUCHENNE trial for SGT-003 and noted that 47 patients have now been dosed in the Phase 1/2 INSPIRE DUCHENNE study, with no reported cases of myocarditis, DILI, or TMA/aHUS to date, and is on track for enrolling 50 patients by June.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences doses part participant in IMPACT DUCHENNE study
- Solid Biosciences receives orphan drug designation for SGT-003 from EC
- Solid Biosciences Adjusts Board Classes in Governance Move
- Solid Biosciences price target raised to $12 from $11 at JPMorgan
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts